The identification of the TMPRSS2:ERG fusion as a frequent molecular alteration occurring in nearly half of prostate cancer cases has revolutionized our comprehension of the underlying mechanisms driving this malignancy. This evidence concerns the gene ERG and prostate carcinoma.